LXRXLexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (LXRX) sells therapeutic candidates for metabolic and cardiovascular diseases, with a focus on sotagliflozin, a drug in Phase III trials for heart failure with reduced ejection fraction. The next catalyst is Nov 5, 2026 — Q2 2025 Earnings Release, which will test the company’s ability to deliver on its clinical and financial roadmap.
- Revenue surged 440.6% YoY to $5.71M, but net income remains -$46.63M, with a net margin of -816.2% TTM.
- Free cash flow is -$116.86M TTM, and debt-to-equity is 0.49x, signaling a leveraged balance sheet.
- Shareholders’ equity stands at $107.54M, with a diluted EPS of -0.07, reflecting ongoing losses.
The Read
Lexicon Pharmaceuticals' past offerings, including the July 1 event, triggered modest median absolute moves of about 4%.
The schedule
- Thu5Nov
The earnings release will test the company's ability to deliver on its clinical trial progress and revenue guidance, following a recent launch of its inpefa therapy. This differs from the last print, which saw underperformance due to delayed trial results.
- Mon9Nov
The earnings release will test the company's ability to deliver on its clinical trial progress and revenue guidance, following a recent launch of its inpefa therapy. This differs from the last print, which saw underperformance due to delayed trial results.
- Thu4Feb
This release will focus on the company's ability to maintain its revenue trajectory and manage cash burn, especially with the ongoing inpefa launch. The last similar print saw a dip due to margin pressures.
- Thu6May
The release will test the company's ability to sustain its revenue growth and manage its debt structure. This differs from the last print, which saw a pullback due to uncertainty in trial outcomes.
Past
- Thu6Aug
Actual outcome: Mixed · $2.34 at outcome
Lexicon Pharmaceuticals reported a quarterly loss of $0.06 per share, in line with the Zacks Consensus Estimate, and highlighted completed enrollment in its Phase III SONATA-HCM trial. The company also outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes, which drove a modest rally despite the earnings miss, as investors focused on the progress in clinical trials and regulatory submissions.
Q2 earnings report expected to clarify Inpefa's initial commercial trajectory following the recent $100M loan facility.
- Wed1Jul
Actual outcome: Mixed · $2.29 at outcome
The stock traded flat, falling just 0.9% during the period, as no definitive capital raise or balance sheet action materialized. While news highlighted Lexicon's advancement of sotagliflozin into new indications and progress in its obesity and pain programs, the market balanced these positive pipeline developments against the lack of immediate funding updates, resulting in a muted price response.
Market evaluation of a potential secondary offering to fund ongoing commercialization of Inpefa.
- Thu7May
Actual outcome: Bull · $1.91 at outcome
Lexicon reported break-even Q1 earnings, outperforming consensus estimates of a $0.04 per share loss, and announced a new $100 million loan facility that significantly bolsters its cash position. The stock ultimately surged past the bull target as investors reacted positively to this strengthened financial flexibility and key pipeline updates, including the anticipated mid-2026 NDA resubmission for ZYNQUISTA and Novo Nordisk's initiation of LX9851 clinical development.
Q1 2026 earnings and an update on Inpefa’s initial commercial trajectory will be the first checkpoint after LXRX’s sharp move to $1.76, with investors focused on prescription trends, gross-to-net discounts, and cash burn direction.
